MX2015003535A - Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. - Google Patents
Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.Info
- Publication number
- MX2015003535A MX2015003535A MX2015003535A MX2015003535A MX2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- dihydropyrrolidino
- pyrimidines
- kinase inhibitors
- present
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 abstract 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702981P | 2012-09-19 | 2012-09-19 | |
| PCT/US2013/060032 WO2014047020A1 (en) | 2012-09-19 | 2013-09-17 | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015003535A true MX2015003535A (es) | 2015-07-14 |
Family
ID=49274870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003535A MX2015003535A (es) | 2012-09-19 | 2013-09-17 | Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9546173B2 (enExample) |
| EP (1) | EP2897961B1 (enExample) |
| JP (1) | JP6186440B2 (enExample) |
| KR (1) | KR20150056550A (enExample) |
| CN (1) | CN104640865B (enExample) |
| AU (1) | AU2013318283A1 (enExample) |
| BR (1) | BR112015005982A2 (enExample) |
| CA (1) | CA2882410A1 (enExample) |
| EA (1) | EA201590600A1 (enExample) |
| ES (1) | ES2612885T3 (enExample) |
| IN (1) | IN2015DN01328A (enExample) |
| MX (1) | MX2015003535A (enExample) |
| WO (1) | WO2014047020A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104640865B (zh) * | 2012-09-19 | 2018-05-11 | 诺华股份有限公司 | 作为激酶抑制剂的二氢吡咯烷子基-嘧啶 |
| US11458124B2 (en) | 2018-07-12 | 2022-10-04 | UCBBiopharma Srl | Spirocyclic indane analogues as IL-17 modulators |
| WO2020243457A1 (en) * | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
| CN114502546A (zh) * | 2019-08-01 | 2022-05-13 | 普拉特戈公司 | 晚期糖基化终产物的抑制剂 |
| ES3018143T3 (en) * | 2019-12-10 | 2025-05-14 | Hoffmann La Roche | New braf inhibitors as paradox breakers |
| IL292161B2 (en) | 2019-12-10 | 2025-04-01 | Hoffmann La Roche | New methylquinazolinone derivatives |
| JP7296017B2 (ja) * | 2020-04-30 | 2023-06-21 | メッドシャイン ディスカバリー インコーポレイテッド | ベンゾスルタムを含む化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004007468A1 (en) * | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| WO2005068468A2 (en) * | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| SI1838718T1 (sl) | 2005-01-10 | 2011-08-31 | Pfizer | Pirolopirazoli, zmogljivi inhibitorji kinaze |
| SI1966151T1 (sl) | 2005-12-13 | 2012-02-29 | Schering Corp | Policikliäśni indazol derivati, ki so erk inhibitorji |
| MY148609A (en) | 2007-06-05 | 2013-05-15 | Merck Sharp & Dohme | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (en) * | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| JP2013542965A (ja) | 2010-11-17 | 2013-11-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 腫瘍の治療方法 |
| ES2543050T3 (es) | 2011-02-28 | 2015-08-14 | Array Biopharma, Inc. | Inhibidores de serina/treonina quinasa |
| JP2015508785A (ja) | 2012-03-02 | 2015-03-23 | ジェネンテック， インコーポレイテッド | ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体 |
| CN104640865B (zh) * | 2012-09-19 | 2018-05-11 | 诺华股份有限公司 | 作为激酶抑制剂的二氢吡咯烷子基-嘧啶 |
-
2013
- 2013-09-17 CN CN201380048493.XA patent/CN104640865B/zh active Active
- 2013-09-17 EP EP13771007.5A patent/EP2897961B1/en active Active
- 2013-09-17 CA CA2882410A patent/CA2882410A1/en not_active Abandoned
- 2013-09-17 WO PCT/US2013/060032 patent/WO2014047020A1/en not_active Ceased
- 2013-09-17 JP JP2015533126A patent/JP6186440B2/ja active Active
- 2013-09-17 KR KR1020157006602A patent/KR20150056550A/ko not_active Withdrawn
- 2013-09-17 EA EA201590600A patent/EA201590600A1/ru unknown
- 2013-09-17 ES ES13771007.5T patent/ES2612885T3/es active Active
- 2013-09-17 MX MX2015003535A patent/MX2015003535A/es unknown
- 2013-09-17 US US14/428,546 patent/US9546173B2/en active Active
- 2013-09-17 IN IN1328DEN2015 patent/IN2015DN01328A/en unknown
- 2013-09-17 AU AU2013318283A patent/AU2013318283A1/en not_active Abandoned
- 2013-09-17 BR BR112015005982A patent/BR112015005982A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2897961B1 (en) | 2016-10-26 |
| CN104640865A (zh) | 2015-05-20 |
| EP2897961A1 (en) | 2015-07-29 |
| CN104640865B (zh) | 2018-05-11 |
| WO2014047020A1 (en) | 2014-03-27 |
| CA2882410A1 (en) | 2014-03-27 |
| EA201590600A1 (ru) | 2015-07-30 |
| AU2013318283A1 (en) | 2015-03-05 |
| US9546173B2 (en) | 2017-01-17 |
| JP2015529248A (ja) | 2015-10-05 |
| JP6186440B2 (ja) | 2017-08-23 |
| KR20150056550A (ko) | 2015-05-26 |
| US20150274733A1 (en) | 2015-10-01 |
| IN2015DN01328A (enExample) | 2015-07-03 |
| BR112015005982A2 (pt) | 2017-07-04 |
| ES2612885T3 (es) | 2017-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
| CA2871471C (en) | Dna-pk inhibitors | |
| PH12013500299B1 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| JO3452B1 (ar) | بنزاميدات أمينو اريل مغاير كمثبطات كيناز | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MY177344A (en) | Compounds and their methods of use | |
| UA111386C2 (uk) | Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ | |
| MX2015003535A (es) | Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| CA2878796C (en) | Derivatives of pyridinone as inhibitors for tissue transglutaminase | |
| PH12018502376A1 (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
| WO2014138616A3 (en) | Pyrazole compounds and methods of use thereof | |
| UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази | |
| MY192305A (en) | Bipyrazole derivatives as jak inhibitors | |
| MX2011003390A (es) | Compuestos y composiciones útiles en el tratamiento de enfermedades cardiacas con efectos secundarios reducidos. |